- OUTLOOK
Will the reclassification of multiple myeloma change how people are treated?
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 51 print issues and online access
$199.00 per year
only $3.90 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Nature 587, S56-S57 (2020)
doi: https://doi.org/10.1038/d41586-020-03224-1
This article is part of Nature Outlook: Multiple myeloma, an editorially independent supplement produced with the financial support of third parties. About this content.
References
Kuehl, W. M. & Bergsagel, P. L. J. Clin. Invest. 122, 3456–3463 (2012).
Kumar, S. et al. J. Clin. Oncol. 38, 8509 (2020).
Corre, J. et al. Haematologica https://doi.org/10.3324/haematol.2019.236588 (2020).
Kristinsson, S. Y., Anderson, W. F. & Landgren, O. Leukemia 28, 1346–1348 (2014).
Jiménez, C. et al. J. Mol. Diagnost. 19, 99–106 (2017).
D’Agostino, M. & Raje, N. Leukemia 34, 21–34 (2020).